During the past decade, Chattanooga Medical Research, LLC conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 17 clinical trials were completed, i.e. on average, 81% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 6 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chattanooga Medical Research, LLC" #1 sponsor was "Bayer" with 3 trials, followed by "Noven Therapeutics" with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "TherapeuticsMD" with 3 trials sponsored and "Becton, Dickinson and Company" with 3 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chattanooga Medical Research, LLC" #1 collaborator was "Alder Biopharmaceuticals, Inc." with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Iqvia Pty Ltd" with 1 trials as a collaborator and "Synteract, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Chattanooga Medical Research, LLC" are "Endometriosis" (4 trials), "Hot Flashes" (3 trials), "Menorrhagia" (3 trials), "Contraception" (2 trials) and "Menopause" (2 trials). Many other conditions were trialed in "Chattanooga Medical Research, LLC" in a lesser frequency.

Most popular intervention types in "Chattanooga Medical Research, LLC" are "Drug" (27 trials), "Device" (8 trials), "Procedure" (3 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Brisdelle (paroxetine mesylate)" (3 trials), "200 mg linzagolix tablet" (2 trials), "75 mg linzagolix tablet" (2 trials) and "Add-back capsule (E2 1 mg / NETA 0.5 mg)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Chattanooga Medical Research, LLC" are 29 trials for "Female" genders and 6 trials for "All" genders.

Currently, there are NaN active trials in "Chattanooga Medical Research, LLC". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Chattanooga Medical Research, LLC, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Chattanooga Medical Research, LLC, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".